Narrow-moat Steris had a good start to its 2022 fiscal year, its first as a combined company with Cantel. We are maintaining our $189 fair value estimate, and we see shares as moderately overvalued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback